D
WAVE Life Sciences Ltd.
WVE
$5.65
$0.173.10%
D
Sell
7/8/2024Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 7/8/2024 due to an increase in the volatility index and valuation index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 7/8/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/18/2024Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 6/18/2024 due to a decline in the volatility index and valuation index.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 6/18/2024 due to a decline in the volatility index and valuation index.
D
Sell
5/15/2024Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 5/15/2024 due to a major increase in the growth index, total return index and volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 5/15/2024 due to a major increase in the growth index, total return index and volatility index.
E
Sell
4/26/2024Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 4/26/2024 due to a substantial decline in the growth index and valuation index. EBIT declined 520.39% from $4.44M to -$18.68M, earnings per share declined from $0.066 to -$0.1507, and total revenue declined 40.96% from $49.21M to $29.06M.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 4/26/2024 due to a substantial decline in the growth index and valuation index. EBIT declined 520.39% from $4.44M to -$18.68M, earnings per share declined from $0.066 to -$0.1507, and total revenue declined 40.96% from $49.21M to $29.06M.
D
Sell
8/7/2023Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 8/7/2023 due to an increase in the growth index, volatility index and total return index. Total revenue increased 70.98% from $12.93M to $22.11M, earnings per share increased from -$0.2685 to -$0.2001, and EBIT increased 22.49% from -$30.29M to -$23.47M.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 8/7/2023 due to an increase in the growth index, volatility index and total return index. Total revenue increased 70.98% from $12.93M to $22.11M, earnings per share increased from -$0.2685 to -$0.2001, and EBIT increased 22.49% from -$30.29M to -$23.47M.
E
Sell
8/4/2023Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 8/4/2023 due to a decline in the total return index, growth index and volatility index.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 8/4/2023 due to a decline in the total return index, growth index and volatility index.
D
Sell
7/20/2023Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 7/20/2023 due to a noticeable increase in the growth index and volatility index. Total revenue increased 943.5% from $1.24M to $12.93M, operating cash flow increased 355.75% from -$33.44M to $85.52M, and earnings per share increased from -$0.465 to -$0.2685.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 7/20/2023 due to a noticeable increase in the growth index and volatility index. Total revenue increased 943.5% from $1.24M to $12.93M, operating cash flow increased 355.75% from -$33.44M to $85.52M, and earnings per share increased from -$0.465 to -$0.2685.
E
Sell
4/26/2023Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 4/26/2023 due to a noticeable decline in the growth index, volatility index and solvency index. Debt to equity increased from -1.09 to -0.12, the quick ratio declined from 1.9 to 1.24, and operating cash flow declined 30.39% from -$25.65M to -$33.44M.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 4/26/2023 due to a noticeable decline in the growth index, volatility index and solvency index. Debt to equity increased from -1.09 to -0.12, the quick ratio declined from 1.9 to 1.24, and operating cash flow declined 30.39% from -$25.65M to -$33.44M.
D
Sell
3/14/2023Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D+ on 03/14/2023.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D+ on 03/14/2023.
D
Sell
3/13/2023Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D+ from D on 3/13/2023 due to an increase in the total return index and volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D+ from D on 3/13/2023 due to an increase in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 2.31 to 1.9.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 2.31 to 1.9.
D
Sell
6/21/2022Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index and total return index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 6/21/2022 due to an increase in the volatility index and total return index.
D
Sell
6/3/2022Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 6/3/2022 due to a decline in the volatility index and total return index.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 6/3/2022 due to a decline in the volatility index and total return index.
D
Sell
5/16/2022Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from E+ on 05/16/2022.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index. The quick ratio declined from 2.35 to 1.91.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index. The quick ratio declined from 2.35 to 1.91.
D
Sell
5/5/2022Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 04/20/2022.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 04/20/2022.
D
Sell
3/4/2022Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/4/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.1229 to -$0.6082, EBIT declined 374.69% from -$7.61M to -$36.11M, and total revenue declined 95.15% from $36.42M to $1.77M.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/4/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.1229 to -$0.6082, EBIT declined 374.69% from -$7.61M to -$36.11M, and total revenue declined 95.15% from $36.42M to $1.77M.
D
Sell
11/11/2021Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from E+ on 11/11/2021 due to a major increase in the growth index and valuation index. Total revenue increased 1,212.07% from $2.78M to $36.42M, earnings per share increased from -$0.7757 to -$0.1229, and EBIT increased 80.9% from -$39.83M to -$7.61M.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from E+ on 11/11/2021 due to a major increase in the growth index and valuation index. Total revenue increased 1,212.07% from $2.78M to $36.42M, earnings per share increased from -$0.7757 to -$0.1229, and EBIT increased 80.9% from -$39.83M to -$7.61M.
E
Sell
11/8/2021Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.07 to 0.18, and the quick ratio declined from 3.67 to 3.08.
WAVE Life Sciences Ltd. (WVE) was downgraded to E+ from D- on 11/8/2021 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.07 to 0.18, and the quick ratio declined from 3.67 to 3.08.
D
Sell
5/14/2021Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 5/14/2021 due to a decline in the valuation index, total return index and growth index. Earnings per share declined from -$0.5902 to -$0.8648, operating cash flow declined 41.25% from -$31.42M to -$44.38M, and EBIT declined 28.94% from -$33.71M to -$43.47M.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 5/14/2021 due to a decline in the valuation index, total return index and growth index. Earnings per share declined from -$0.5902 to -$0.8648, operating cash flow declined 41.25% from -$31.42M to -$44.38M, and EBIT declined 28.94% from -$33.71M to -$43.47M.
D
Sell
11/27/2020Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 11/27/2020 due to an increase in the total return index and volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 11/27/2020 due to an increase in the total return index and volatility index.
D
Sell
11/5/2020Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 11/5/2020 due to a decline in the volatility index and total return index.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 11/5/2020 due to a decline in the volatility index and total return index.
D
Sell
10/21/2020Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 10/21/2020 due to an increase in the volatility index and valuation index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 10/21/2020 due to an increase in the volatility index and valuation index.
D
Sell
10/5/2020Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 10/5/2020 due to a decline in the volatility index.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 10/5/2020 due to a decline in the volatility index.
D
Sell
9/1/2020Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 9/1/2020 due to an increase in the total return index and volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 9/1/2020 due to an increase in the total return index and volatility index.
D
Sell
8/12/2020Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 8/12/2020 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 45.31% from -$26.25M to -$38.15M, and total revenue declined 27.25% from $4.16M to $3.03M.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 8/12/2020 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 45.31% from -$26.25M to -$38.15M, and total revenue declined 27.25% from $4.16M to $3.03M.
D
Sell
5/13/2020Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 5/13/2020 due to a large increase in the growth index and valuation index. Total revenue increased 73.38% from $2.4M to $4.16M, operating cash flow increased 57.14% from -$61.24M to -$26.25M, and EBIT increased 17.41% from -$60.53M to -$49.99M.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 5/13/2020 due to a large increase in the growth index and valuation index. Total revenue increased 73.38% from $2.4M to $4.16M, operating cash flow increased 57.14% from -$61.24M to -$26.25M, and EBIT increased 17.41% from -$60.53M to -$49.99M.
D
Sell
3/15/2018Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/15/2018 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 11.14 to 7.26, net income declined 15.6% from -$26.14M to -$30.21M, and total capital declined 15% from $173.76M to $147.7M.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/15/2018 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 11.14 to 7.26, net income declined 15.6% from -$26.14M to -$30.21M, and total capital declined 15% from $173.76M to $147.7M.
D
Sell
12/13/2017Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 12/13/2017 due to an increase in the total return index and volatility index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 12/13/2017 due to an increase in the total return index and volatility index.
D
Sell
11/28/2017Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 11/28/2017 due to a decline in the valuation index.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 11/28/2017 due to a decline in the valuation index.
D
Sell
11/13/2017Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 11/13/2017 due to an increase in the valuation index and efficiency index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 11/13/2017 due to an increase in the valuation index and efficiency index.
D
Sell
3/21/2017Downgrade
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/21/2017 due to a decline in the efficiency index, total return index and solvency index. The quick ratio declined from 15.01 to 12.36, total capital declined 10.24% from $159.1M to $142.82M, and net income declined 5.24% from -$17.54M to -$18.45M.
WAVE Life Sciences Ltd. (WVE) was downgraded to D- from D on 3/21/2017 due to a decline in the efficiency index, total return index and solvency index. The quick ratio declined from 15.01 to 12.36, total capital declined 10.24% from $159.1M to $142.82M, and net income declined 5.24% from -$17.54M to -$18.45M.
D
Sell
12/1/2016Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 12/1/2016 due to an increase in the total return index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D from D- on 12/1/2016 due to an increase in the total return index.
D
Sell
8/1/2016Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 8/1/2016 due to a major increase in the total return index.
WAVE Life Sciences Ltd. (WVE) was upgraded to D- from E+ on 8/1/2016 due to a major increase in the total return index.
E
Sell
5/23/2016Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to E+ from E on 5/23/2016 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4634 to -$0.3641.
WAVE Life Sciences Ltd. (WVE) was upgraded to E+ from E on 5/23/2016 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4634 to -$0.3641.
E
Sell
5/2/2016Upgraded
WAVE Life Sciences Ltd. (WVE) was upgraded to E from E- on 5/2/2016 due to a significant increase in the solvency index, growth index and efficiency index. Total capital increased 139.08% from $67.55M to $161.51M, the quick ratio increased from 19.01 to 42.23, and earnings per share increased from -$0.5352 to -$0.4634.
WAVE Life Sciences Ltd. (WVE) was upgraded to E from E- on 5/2/2016 due to a significant increase in the solvency index, growth index and efficiency index. Total capital increased 139.08% from $67.55M to $161.51M, the quick ratio increased from 19.01 to 42.23, and earnings per share increased from -$0.5352 to -$0.4634.
E
Sell
3/11/2016Downgrade
WAVE Life Sciences Pte. Ltd. (WVE) was downgraded to E- from E on 3/11/2016 due to a noticeable decline in the volatility index and valuation index.
WAVE Life Sciences Pte. Ltd. (WVE) was downgraded to E- from E on 3/11/2016 due to a noticeable decline in the volatility index and valuation index.
E
Sell
2/8/2016None
WAVE Life Sciences Ltd. (WVE) was downgraded to E from U on 02/08/2016.
WAVE Life Sciences Ltd. (WVE) was downgraded to E from U on 02/08/2016.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
